A Randomised, Open-Label, Phase 3 Trial Comparing Amrubicin Versus Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure of First-Line Chemotherapy
Phase of Trial: Phase III
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Amrubicin (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 27 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Oct 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.